Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus PROCARDIA XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus PROCARDIA XL.
DILACOR XR vs PROCARDIA XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
30-90 mg orally once daily, extended-release tablet.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker